biote Management
Management criteria checks 2/4
biote's CEO is Bret Christensen, appointed in Feb 2025, has a tenure of 1.25 years. total yearly compensation is $5.08M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $86.81K. The average tenure of the management team and the board of directors is 2.2 years and 4 years respectively.
Key information
Bret Christensen
Chief executive officer
US$5.1m
Total compensation
| CEO salary percentage | 12.65% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.2yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Narrative Update • May 02
BTMD: Recall Disruption And Higher Investment Spend Will Set Up Later Upside
Narrative Update Analysts have trimmed the average price target for biote by about $0.20 as they factor in a lower fair value estimate, a higher assumed future P/E, and recent research pointing to recall related pressures, increased investment plans, and mixed clinic growth trends. Analyst Commentary Recent research updates on biote point to a mixed setup, with analysts weighing near term recall and investment headwinds against execution on sales initiatives and clinic growth potential.
Narrative Update • Apr 17
BTMD: Recall Resolution And Clinic Productivity Investments Will Support Future Upside
The average analyst price target on biote has been reduced to about $4 from roughly $6, as analysts factor in lower forecast revenue growth, slimmer projected profit margins, a higher discount rate, and a much higher assumed future P/E multiple following recent guidance updates and the impacts of the product recall. Analyst Commentary Recent Street research reflects a reset in expectations, but it also highlights areas where bullish analysts still see room for value creation if biote executes on its plans and manages the recall process effectively.Narrative Update • Apr 03
BTMD: Affordable Medicines Theme Will Support Upside As Investments Settle
Analysts have trimmed biote's average price target as firms reset expectations to a lower range of $2 to $5, citing the impact of a voluntary recall, higher operating investments, and slower clinic growth, even as they acknowledge progress on sales execution and systems upgrades. Analyst Commentary Recent research highlights a reset in expectations around biote, with lower price targets reflecting near term operational and growth headwinds, alongside recognition of execution progress and investments aimed at future expansion.
Narrative Update • Mar 20
BTMD: Affordable Medicines Theme Will Support Upside As 2026 Plan Advances
Analysts have trimmed the consolidated price target for biote to a range of about $2 to $3. This reflects more cautious assumptions on growth and profitability following guidance tied to the voluntary recall, higher investment, and slower clinic expansion.Narrative Update • Mar 06
BTMD: Affordable Medicines Theme Will Drive Upside Despite Recent Cautious Reassessment
Analysts recently trimmed their 12 month price target on biote to $5 from $6, with the change tied to updated views on discount rates, revenue growth potential, profit margins, and a slightly higher assumed future P/E multiple, while still citing the broader affordable medicines theme as a key part of the thesis heading into 2026. Analyst Commentary Recent Street research has highlighted a more cautious tone around biote, with the 12 month price target trimmed to $5 from $6.Narrative Update • Feb 20
BTMD: Affordable Medicines Theme Will Support Upside Case Despite Lower Street Expectations
Analysts have trimmed their price target on biote to $5 from $6, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E. They continue to highlight the company’s fit within the broader affordable medicines theme.Narrative Update • Feb 05
BTMD: Affordable Medicines Theme Will Support Upside Potential Despite Lowered Expectations
Narrative update on biote Analysts have trimmed their price target on biote to US$5 from US$6, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while still highlighting affordable medicines as a supportive theme heading into 2026. Analyst Commentary Recent research reflects a more cautious stance on biote's share price while still pointing to the affordable medicines theme as an important support for the story heading into 2026.Narrative Update • Jan 22
BTMD: Affordable Medicines Theme Will Support Reassessed Outlook Into 2026
Analysts recently trimmed their price target on biote to $5 from $6, citing a mix of updated assumptions on fair value, discount rate, growth, margins, and future P/E expectations as they reassessed the stock within the broader affordable medicines theme heading into 2026. Analyst Commentary Recent Street research on Biote has focused on recalibrating expectations around valuation, execution, and growth, with some Bearish analysts taking a more cautious stance even as the broader affordable medicines theme remains in focus heading into 2026.Narrative Update • Jan 07
BTMD: Affordable Medicines Theme And Buybacks Will Support Upside Potential
Analysts have trimmed their price target on biote to $5 from $6, citing a still supportive view on the affordable medicines theme, even as they fine tune assumptions for revenue growth, margins, and future P/E expectations. Analyst Commentary Even with the trimmed price target, bullish analysts continue to frame biote within the affordable medicines theme, suggesting they still see room for the shares to reflect that positioning over time.Narrative Update • Dec 13
BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook
Analysts have modestly raised their price target on biote to reflect stronger expected revenue growth and a higher future earnings multiple, partially offset by more conservative margin and discount rate assumptions. What's in the News biote Corp.Seeking Alpha • Sep 10
Restructuring At Biote Will Drive Greater Growth And Profitability
Summary I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance. Valuation remains attractive with significant upside to intrinsic value, but investors should monitor debt levels, potential dilution, and execution risks. Read the full article on Seeking AlphaAnalysis Article • Aug 09
Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
One of the biggest stories of last week was how biote Corp. ( NASDAQ:BTMD ) shares plunged 26% in the week since its...Narrative Update • Aug 08
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
The significant drop in biote’s net profit margin combined with a sharply higher future P/E suggests deteriorating profitability and a less attractive valuation outlook, leading to the consensus analyst price target being revised down from $6.40 to $4.98. What's in the News Biote Corp.Analysis Article • Aug 08
Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet
NasdaqGM:BTMD 1 Year Share Price vs Fair Value Explore biote's Fair Values from the Community and select yours biote...Analysis Article • May 10
biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
biote Corp. ( NASDAQ:BTMD ) investors will be delighted, with the company turning in some strong numbers with its...Analysis Article • May 09
Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings
With a price-to-earnings (or "P/E") ratio of 37.3x biote Corp. ( NASDAQ:BTMD ) may be sending very bearish signals at...Analysis Article • Dec 02
biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward
biote Corp. ( NASDAQ:BTMD ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Analysis Article • Sep 27
Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.9x biote Corp. ( NASDAQ:BTMD ) is definitely a stock...
New Narrative • Sep 26
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.Seeking Alpha • Sep 27
biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside
Truist has initiated biote Corp. (NASDAQ:BTMD) with a buy rating highlighting the company's leadership in providing bioidentical hormone replacement therapy to improve hormonal imbalance. The firm has a $10 price target (~138% upside based on Monday's close). Analyst Gregory Fraser said that the company's platform "provides physicians with effective treatment options as well as a source of income" and added that the model has led to revenue and EBITDA growth. He noted that biote's (BTMD) growth strategy is focused on increasing utlilization of both existing and new partner clinics. Truist conducted a survey of 25 physicians who use biote's (BTMD) bioidentical hormone replacement therapy and found they expect to prescribe more of the company's pellet therapy over the next year. Seeking Alpha's Quant Rating views biote (BTMD) as a strong buy.Seeking Alpha • Sep 07
Biote partners with IMAC Holdings
biote Corp (NASDAQ:BTMD) said it had entered into a partnership with IMAC Holdings, to add the latter's services to its network of outpatient clinics that deliver orthopedic, regenerative, and advanced, non-surgical medical procedures. The Company said it had begun training IMAC medical professionals in the Biote Method for launching the treatments at select IMAC Regeneration Centers in September. "We are excited to add Biote’s services to IMAC clinics, which will be used to implement innovative weight loss and hormone optimization therapy within our current patient population," said Jeff Ervin, IMAC Founder and Chief Executive Officer. IMAC Holdings deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$16m |
| Dec 31 2025 | US$5m | US$642k | US$27m |
Compensation vs Market: Bret's total compensation ($USD5.08M) is above average for companies of similar size in the US market ($USD647.77K).
Compensation vs Earnings: Insufficient data to compare Bret's compensation with company performance.
CEO
Bret Christensen (54 yo)
1.3yrs
Tenure
US$5,075,718
Compensation
Mr. Bret Christensen is Director of Neurolutions, Inc. (also known as Kandu, Inc.) from October 2025. Mr. Christensen serves as CEO & Director of biote Corp. since February 1, 2025. He served as Chief Exec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$5.08m | 0.12% $ 86.8k | |
| CFO & Chief Business Officer | 2.3yrs | US$1.45m | no data | |
| VP of Business Development | 4.9yrs | US$1.67m | no data | |
| Chief Information Officer | 2.1yrs | no data | no data | |
| Chief Marketing Officer | 1.3yrs | no data | no data | |
| Chief Digital Officer | 5.3yrs | no data | no data | |
| Head of Nutraceuticals | 4yrs | no data | no data | |
| Chief Clinical Advisor & Member of Medical Advisory Board | no data | no data | no data | |
| SVP of Strategy & Commercial Operations | less than a year | no data | no data |
2.2yrs
Average Tenure
54yo
Average Age
Experienced Management: BTMD's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$5.08m | 0.12% $ 86.8k | |
| Chief Clinical Advisor & Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4yrs | US$323.93k | 8.18% $ 5.7m | |
| Non-Executive Chairman of the Board | 5.3yrs | US$1.56m | 0.36% $ 248.9k | |
| Independent Director | 3.5yrs | US$326.74k | 0.24% $ 165.2k | |
| Lead Independent Director | less than a year | US$389.35k | no data | |
| Chair of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$313.38k | 0.53% $ 371.4k | |
| Independent Director | 4yrs | US$327.44k | 0.21% $ 147.7k | |
| Senior Medical Advisor & Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
4.0yrs
Average Tenure
60yo
Average Age
Experienced Board: BTMD's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/18 21:28 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
biote Corp. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Kaumil Gajrawala | Jefferies LLC |
| George Kelly | Roth Capital Partners |